BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 28714107)

  • 21. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
    Tschandl P; Berghoff AS; Preusser M; Burgstaller-Muehlbacher S; Pehamberger H; Okamoto I; Kittler H
    PLoS One; 2013; 8(7):e69639. PubMed ID: 23861977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification.
    Moreno S; Maiques O; Barcelo C; Romero M; Santacana M; Gómez I; Cuevas D; Velasco A; Vea A; Macia A; Boix R; Valls J; Gatius S; Canti C; Matias-Guiu X; Soria X; Marti RM
    Acta Derm Venereol; 2021 Nov; 101(11):adv00597. PubMed ID: 34643739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
    Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
    Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
    Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
    Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biology and genetics of acquired and congenital melanocytic naevi.
    Maher NG; Scolyer RA; Colebatch AJ
    Pathology; 2023 Mar; 55(2):169-177. PubMed ID: 36635156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
    Uribe P; Andrade L; Gonzalez S
    J Invest Dermatol; 2006 Jan; 126(1):161-6. PubMed ID: 16417232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aggressive melanoma in an infant with congenital melanocytic nevus syndrome and multiple, NRAS and BRAF mutation-negative nodules.
    de la Rosa Carrillo D; Vindenes H; Kinsler VA; Rønnestad A; Ringstad G; Müller LO; Tafjord S; Tønseth KA; Kvamme B; Clausen OPF
    Pediatr Dermatol; 2018 Sep; 35(5):e281-e285. PubMed ID: 29999207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-sectional analysis of the dermoscopic patterns and structures of melanocytic naevi on the back and legs of adolescents.
    Fonseca M; Marchetti MA; Chung E; Dusza SW; Burnett ME; Marghoob AA; Geller AC; Bishop M; Scope A; Halpern AC
    Br J Dermatol; 2015 Dec; 173(6):1486-1493. PubMed ID: 26189624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
    Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activating BRAF mutations in eruptive melanocytic naevi.
    Sekulic A; Colgan MB; Davis MD; DiCaudo DJ; Pittelkow MR
    Br J Dermatol; 2010 Nov; 163(5):1095-8. PubMed ID: 20716222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Genomic Profiling of Melanocytic Nevi.
    Colebatch AJ; Ferguson P; Newell F; Kazakoff SH; Witkowski T; Dobrovic A; Johansson PA; Saw RPM; Stretch JR; McArthur GA; Long GV; Thompson JF; Pearson JV; Mann GJ; Hayward NK; Waddell N; Scolyer RA; Wilmott JS
    J Invest Dermatol; 2019 Aug; 139(8):1762-1768. PubMed ID: 30772300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.
    Thomas NE; Edmiston SN; Orlow I; Kanetsky PA; Luo L; Gibbs DC; Parrish EA; Hao H; Busam KJ; Armstrong BK; Kricker A; Cust AE; Anton-Culver H; Gruber SB; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Dwyer T; Ollila DW; Begg CB; Berwick M; Conway K;
    J Invest Dermatol; 2018 Nov; 138(11):2398-2404. PubMed ID: 29753029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.
    Gouillon L; Perier-Muzet M; Amini-Adle M; Poulalhon N; Debarbieux S; Boespflug A; Balme B; Depaepe L; Harou O; Lopez J; Bringuier PP; Ferraro-Peyret C; Maucort-Boulch D; Robinson P; Thomas L; Dalle S
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e57-e59. PubMed ID: 31442328
    [No Abstract]   [Full Text] [Related]  

  • 38. The molecular profile of metastatic melanoma in Australia.
    Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
    Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
    Evrenos MK; Temiz P; Çam FS; Yaman M; Yoleri L; Ermertcan AT
    Turk J Med Sci; 2018 Oct; 48(5):973-979. PubMed ID: 30384563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma.
    Hsieh R; Nico MM; Camillo CM; Oliveira KK; Sangueza M; Lourenço SV
    Am J Dermatopathol; 2017 Feb; 39(2):104-110. PubMed ID: 28134726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.